Skip to main content

Review of PET/CT Images in Melanoma and Sarcoma: False Positives, False Negatives, and Pitfalls

  • Chapter
  • First Online:
PET/CT and PET/MR in Melanoma and Sarcoma
  • 412 Accesses

Abstract

The most common cause of false-positive PET is inflammation, whether infectious or otherwise. Recent local therapy, such as surgery or radiation, will produce inflammation that can persist for months. Surgery can produce reactive uptake in local soft tissues and nodes, and the interpreter should be aware of changes in highly active tissues (such as a neobladder). Radiation can produce intense uptake, but is often in a linear pattern. Granulomatous inflammation (autoimmune or infectious) can produce false positives due to its intensity and nodularity. Access to the patient history is thus useful. False negatives may be seen in high-background organs such as the brain (necessitating a brain MR for full staging) or kidneys and bladder. Muscle metastases may be difficult to detect on CT, whereas bone metastases may be only detectable on CT. Brown fat in the neck is intense but has a characteristic pattern that should be recognized. Lesions below a centimeter cannot be reliably detected, though they are sometimes visible. A variety of motion artifacts, most commonly due to musculoskeletal motion or breathing, can cause errors in attenuation correction and/or anatomic correlation. Non-attenuation-corrected images may be useful here. Sites at the border of the imaging field may be poorly visualized. Intense physiologic uptake may obscure uptake in nearby metastases. Incidental findings are relatively common, particularly in the thyroid and colon, and should be noted as they may represent another primary malignancy. Finally, incidental findings on CT such as pneumothorax may be important as well.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kumar R, Mavi A, Bural G, Alavi A. Fluorodeoxyglucose-PET in the management of malignant melanoma. Radiol Clin N Am. 2005;43(1):23–33.

    Article  Google Scholar 

  2. Wallitt K, Yusuf S, Soneji N, Khan SR, Win Z, Barwick TD. PET/CT in oncologic imaging of nodal disease: pearls and pitfalls: RadioGraphics fundamentals | online presentation. Radiographics. 2018;38(2):564–5.

    Article  Google Scholar 

  3. Lococo F, Muoio B, Chiappetta M, Nachira D, Petracca Ciavarella L, Margaritora S, et al. Diagnostic performance of PET or PET/CT with different radiotracers in patients with suspicious lung cancer or pleural tumours according to published meta-analyses. Contrast Media Mol Imaging. 2020;5282698:2020.

    Google Scholar 

  4. Bourgeois AC, Chang TT, Fish LM, Bradley YC. Positron emission tomography/computed tomography in melanoma. Radiol Clin N Am. 2013;51(5):865–79.

    Article  Google Scholar 

  5. Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328–54.

    Article  CAS  Google Scholar 

  6. Sachpekidis C, Kopp-Schneider A, Hakim-Meibodi L, Dimitrakopoulou-Strauss A, Hassel JC. 18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab. Melanoma Res. 2019;29(2):178–86.

    Article  CAS  Google Scholar 

  7. Sachpekidis C, Larribere L, Kopp-Schneider A, Hassel JC, Dimitrakopoulou-Strauss A. Can benign lymphoid tissue changes in (18)F-FDG PET/CT predict response to immunotherapy in metastatic melanoma? Cancer Immunol Immunother. 2019;68(2):297–303.

    Article  CAS  Google Scholar 

  8. Nobashi T, Baratto L, Reddy SA, Srinivas S, Toriihara A, Hatami N, et al. Predicting response to immunotherapy by evaluating tumors, lymphoid cell-rich organs, and immune-related adverse events using FDG-PET/CT. Clin Nucl Med. 2019;44(4):e272–9.

    Article  Google Scholar 

  9. Lang N, Dick J, Slynko A, Schulz C, Dimitrakopoulou-Strauss A, Sachpekidis C, et al. Clinical significance of signs of autoimmune colitis in (18)F-fluorodeoxyglucose positron emission tomography-computed tomography of 100 stage-IV melanoma patients. Immunotherapy. 2019;11(8):667–76.

    Article  CAS  Google Scholar 

  10. Goldfarb L, Duchemann B, Chouahnia K, Zelek L, Soussan M. Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST. EJNMMI Res. 2019;9(1):8.

    Article  Google Scholar 

  11. Ito K, Teng R, Schoder H, Humm JL, Ni A, Michaud L, et al. (18)F-FDG PET/CT for monitoring of ipilimumab therapy in patients with metastatic melanoma. J Nucl Med. 2019;60(3):335–41.

    Article  CAS  Google Scholar 

  12. Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143–52.

    Article  Google Scholar 

  13. Adams MC, Turkington TG, Wilson JM, Wong TZ. A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol. 2010;195(2):310–20.

    Article  Google Scholar 

  14. Treglia G, Bertagna F, Sadeghi R, Muoio B, Giovanella L. Prevalence and risk of malignancy of focal incidental uptake detected by fluorine-18-fluorodeoxyglucose positron emission tomography in the parotid gland: a meta-analysis. Eur Arch Otorhinolaryngol. 2015;272(12):3617–26.

    Article  Google Scholar 

  15. Nayan S, Ramakrishna J, Gupta MK. The proportion of malignancy in incidental thyroid lesions on 18-FDG PET study: a systematic review and meta-analysis. Otolaryngol Head Neck Surg. 2014;151(2):190–200.

    Article  Google Scholar 

  16. Treglia G, Bertagna F, Sadeghi R, Verburg FA, Ceriani L, Giovanella L. Focal thyroid incidental uptake detected by (1)(8)F-fluorodeoxyglucose positron emission tomography. Meta-analysis on prevalence and malignancy risk. Nuklearmedizin. 2013;52(4):130–6.

    Article  CAS  Google Scholar 

  17. Shie P, Cardarelli R, Sprawls K, Fulda KG, Taur A. Systematic review: prevalence of malignant incidental thyroid nodules identified on fluorine-18 fluorodeoxyglucose positron emission tomography. Nucl Med Commun. 2009;30(9):742–8.

    Article  Google Scholar 

  18. Bertagna F, Treglia G, Orlando E, Dognini L, Giovanella L, Sadeghi R, et al. Prevalence and clinical significance of incidental F18-FDG breast uptake: a systematic review and meta-analysis. Jpn J Radiol. 2014;32(2):59–68.

    Article  CAS  Google Scholar 

  19. Benveniste AP, Marom EM, Benveniste MF, Mawlawi O, Fox PS, Yang W. Incidental primary breast cancer detected on PET-CT. Breast Cancer Res Treat. 2015;151(2):261–8.

    Article  CAS  Google Scholar 

  20. Treglia G, Taralli S, Salsano M, Muoio B, Sadeghi R, Giovanella L. Prevalence and malignancy risk of focal colorectal incidental uptake detected by (18)F-FDG-PET or PET/CT: a meta-analysis. Radiol Oncol. 2014;48(2):99–104.

    Article  Google Scholar 

  21. Adams SJ, Rakheja R, Bryce R, Babyn PS. Incidence and economic impact of incidental findings on (18)F-FDG PET/CT imaging. Can Assoc Radiol J. 2018;69(1):63–70.

    Article  Google Scholar 

  22. MacMahon H, Naidich DP, Goo JM, Lee KS, Leung ANC, Mayo JR, et al. Guidelines for management of incidental pulmonary nodules detected on CT images: from the Fleischner Society 2017. Radiology. 2017;284(1):228–43.

    Article  Google Scholar 

  23. Dong A, Cui Y, Wang Y, Zuo C, Bai Y. (18)F-FDG PET/CT of adrenal lesions. AJR Am J Roentgenol. 2014;203(2):245–52.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jorge Daniel Oldan .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Oldan, J.D. (2021). Review of PET/CT Images in Melanoma and Sarcoma: False Positives, False Negatives, and Pitfalls. In: Khandani, A.H. (eds) PET/CT and PET/MR in Melanoma and Sarcoma. Springer, Cham. https://doi.org/10.1007/978-3-030-60429-5_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-60429-5_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-60428-8

  • Online ISBN: 978-3-030-60429-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics